AstraZeneca's R&D expenditure as a percentage of revenue 2006-2023
This statistic shows AstraZeneca's research & development expenditure as a percentage of its total revenue from 2006 to 2023. In 2023, the company invested 25 percent of its revenue into research and development. AstraZeneca plc is one of the top 10 pharmaceutical companies worldwide. The multinational company is headquartered in London, UK. AstraZeneca is focused on products for following major disease areas: cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. Together with the Oxford University, the company also developed one of the first effective COVID-19 vaccines.